Bulltick Wealth Management LLC Sells 52,467 Shares of Sanofi (NASDAQ:SNY)

Bulltick Wealth Management LLC cut its stake in shares of Sanofi (NASDAQ:SNY) by 46.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,000 shares of the company’s stock after selling 52,467 shares during the period. Bulltick Wealth Management LLC’s holdings in Sanofi were worth $2,911,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Vestal Point Capital LP bought a new stake in shares of Sanofi in the 4th quarter valued at about $14,919,000. Dynamic Advisor Solutions LLC increased its stake in Sanofi by 39.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after purchasing an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC acquired a new stake in Sanofi in the second quarter worth $13,725,000. Mount Yale Investment Advisors LLC boosted its position in shares of Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after purchasing an additional 12,806 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after buying an additional 30,115 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. The stock’s 50-day moving average is $54.34 and its 200-day moving average is $50.48. Sanofi has a one year low of $42.63 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 EPS. Equities analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SNY. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.